Skip to contentA
Amneal Pharmaceuticals, Inc.
A
AMRXAmneal Pharmaceuticals, Inc. Q2 2021 · 10-Q
Revenue$535.08M$535.08M+15.2% vs Q2 2020 Net Income$29.99M$29.99MN/M vs Q2 2020 EPS Diluted$0.10$0.10N/M vs Q2 2020 Gross Profit$212,498,000+47.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amneal Pharmaceuticals, Inc. · CIK 1723128 · Engraved from SEC EDGAR
Operating Cash Flowderived-$51,933,000N/M Free Cash Flowderived-$59,742,000N/M Margins · derivedGross margin39.7%+8.7 pt vs Q2 2020
Operating margin12.5%+10.2 pt vs Q2 2020
Net margin5.6%+10.8 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 9, 2021 · 40 d after period end